<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:50:31 -0700</creation_date>
  <update_date>2013-05-27 11:07:09 -0600</update_date>
  <accession>HMDBP00525</accession>
  <secondary_accessions>
    <accession>5774</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Acylcholine acylhydrolase</synonym>
    <synonym>Butyrylcholine esterase</synonym>
    <synonym>Choline esterase II</synonym>
    <synonym>Pseudocholinesterase</synonym>
  </synonyms>
  <gene_name>BCHE</gene_name>
  <general_function>Involved in carboxylesterase activity</general_function>
  <specific_function>Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05041</accession>
      <name>Donepezil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00097</accession>
      <name>Choline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00910</accession>
      <name>Tridecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00806</accession>
      <name>Myristic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00220</accession>
      <name>Palmitic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06497</accession>
      <name>Heptadecanoyl CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00827</accession>
      <name>Stearic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02212</accession>
      <name>Arachidic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00895</accession>
      <name>Acetylcholine </name>
    </metabolite>
    <metabolite>
      <accession>HMDB02259</accession>
      <name>Heptadecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00826</accession>
      <name>Pentadecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14324</accession>
      <name>Ramipril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14329</accession>
      <name>Pentagastrin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14347</accession>
      <name>Succinylcholine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14526</accession>
      <name>Tacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14535</accession>
      <name>Sulpiride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14536</accession>
      <name>Ethopropazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14592</accession>
      <name>Dipivefrin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14656</accession>
      <name>Cisplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14668</accession>
      <name>Dibucaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14685</accession>
      <name>Pyridostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14723</accession>
      <name>Nizatidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14812</accession>
      <name>Galantamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14815</accession>
      <name>Isoflurophate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14849</accession>
      <name>Diethylcarbamazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14859</accession>
      <name>Procaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14871</accession>
      <name>Pralidoxime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14910</accession>
      <name>Malathion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14928</accession>
      <name>Perindopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14994</accession>
      <name>Chlorphenesin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15009</accession>
      <name>Terbutaline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15029</accession>
      <name>Oxybuprocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15076</accession>
      <name>Hexafluronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15079</accession>
      <name>Demecarium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15114</accession>
      <name>Cyclopentolate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15124</accession>
      <name>Rivastigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15145</accession>
      <name>Edrophonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15169</accession>
      <name>Procainamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15190</accession>
      <name>Echothiophate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15248</accession>
      <name>Trimethaphan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15254</accession>
      <name>Ambenonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15266</accession>
      <name>Doxacurium chloride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15292</accession>
      <name>Chloroprocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15357</accession>
      <name>Mivacurium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15375</accession>
      <name>Decamethonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15430</accession>
      <name>Pancuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15431</accession>
      <name>Pipecuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15451</accession>
      <name>Ephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15467</accession>
      <name>Drospirenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15472</accession>
      <name>Neostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15478</accession>
      <name>Bambuterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00169</accession>
      <name>D-Mannose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00039</accession>
      <name>Butyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01897</accession>
      <name>Substance P</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13930</accession>
      <name>R-95913</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>cholinesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on ester bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carboxylesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum lumen</description>
      <go_id>GO:0005788</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>extracellular space</description>
      <go_id>GO:0005615</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>membrane</description>
      <go_id>GO:0016020</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nuclear envelope lumen</description>
      <go_id>GO:0005641</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>acetylcholinesterase activity</description>
      <go_id>GO:0003990</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>beta-amyloid binding</description>
      <go_id>GO:0001540</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>carboxylesterase activity</description>
      <go_id>GO:0004091</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>choline binding</description>
      <go_id>GO:0033265</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>enzyme binding</description>
      <go_id>GO:0019899</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>choline metabolic process</description>
      <go_id>GO:0019695</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cocaine metabolic process</description>
      <go_id>GO:0050783</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>learning</description>
      <go_id>GO:0007612</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of synaptic transmission</description>
      <go_id>GO:0050805</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to alkaloid</description>
      <go_id>GO:0043279</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to folic acid</description>
      <go_id>GO:0051593</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to glucocorticoid stimulus</description>
      <go_id>GO:0051384</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>synaptic transmission, cholinergic</description>
      <go_id>GO:0007271</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Secreted</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>3</chromosome_location>
    <locus>3q26.1-q26.2</locus>
    <gene_sequence>&gt;1809 bp
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>602</residue_number>
    <molecular_weight>68417.575</molecular_weight>
    <theoretical_pi>7.421</theoretical_pi>
    <pfams>
      <pfam>
        <name>AChE_tetra</name>
        <pfam_id>PF08674</pfam_id>
      </pfam>
      <pfam>
        <name>COesterase</name>
        <pfam_id>PF00135</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>180484</genbank_protein_id>
  <uniprot_id>P06276</uniprot_id>
  <uniprot_name>CHLE_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1EHO</pdb_id>
    <pdb_id>1EHQ</pdb_id>
    <pdb_id>1KCJ</pdb_id>
    <pdb_id>1P0I</pdb_id>
    <pdb_id>1P0M</pdb_id>
    <pdb_id>1P0P</pdb_id>
    <pdb_id>1P0Q</pdb_id>
    <pdb_id>1XLU</pdb_id>
    <pdb_id>1XLV</pdb_id>
    <pdb_id>1XLW</pdb_id>
    <pdb_id>2J4C</pdb_id>
    <pdb_id>2PM8</pdb_id>
    <pdb_id>2WID</pdb_id>
    <pdb_id>2WIF</pdb_id>
    <pdb_id>2WIG</pdb_id>
    <pdb_id>2WIJ</pdb_id>
    <pdb_id>2WIK</pdb_id>
    <pdb_id>2WIL</pdb_id>
    <pdb_id>2WSL</pdb_id>
    <pdb_id>2XMB</pdb_id>
    <pdb_id>2XMC</pdb_id>
    <pdb_id>2XMD</pdb_id>
    <pdb_id>2XMG</pdb_id>
    <pdb_id>2XQF</pdb_id>
    <pdb_id>2XQG</pdb_id>
    <pdb_id>2XQI</pdb_id>
    <pdb_id>2XQJ</pdb_id>
    <pdb_id>2XQK</pdb_id>
    <pdb_id>2Y1K</pdb_id>
    <pdb_id>3DJY</pdb_id>
    <pdb_id>3DKK</pdb_id>
    <pdb_id>3O9M</pdb_id>
    <pdb_id>4AQD</pdb_id>
    <pdb_id>4AXB</pdb_id>
    <pdb_id>4B0O</pdb_id>
    <pdb_id>4B0P</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M16541</genbank_gene_id>
  <genecard_id>BCHE</genecard_id>
  <geneatlas_id>BCHE</geneatlas_id>
  <hgnc_id>HGNC:983</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31.</reference_text>
      <pubmed_id>2322535</pubmed_id>
    </reference>
    <reference>
      <reference_text>Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H: Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3555-9.</reference_text>
      <pubmed_id>3035536</pubmed_id>
    </reference>
    <reference>
      <reference_text>McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O: Brain cDNA clone for human cholinesterase.  Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6.</reference_text>
      <pubmed_id>3477799</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase.  J Biol Chem. 1987 Jan 15;262(2):549-57.</reference_text>
      <pubmed_id>3542989</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lockridge O, Adkins S, La Du BN: Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52.</reference_text>
      <pubmed_id>3115973</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bunkenborg J, Pilch BJ, Podtelejnikov AV, Wisniewski JR: Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics. 2004 Feb;4(2):454-65.</reference_text>
      <pubmed_id>14760718</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.</reference_text>
      <pubmed_id>16335952</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chilukuri N, Duysen EG, Parikh K, diTargiani R, Doctor BP, Lockridge O, Saxena A: Adenovirus-transduced human butyrylcholinesterase in mouse blood functions as a bioscavenger of chemical warfare nerve agents. Mol Pharmacol. 2009 Sep;76(3):612-7. Epub 2009 Jun 19.</reference_text>
      <pubmed_id>19542320</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61.</reference_text>
      <pubmed_id>19159218</pubmed_id>
    </reference>
    <reference>
      <reference_text>Amitay M, Shurki A: The structure of G117H mutant of butyrylcholinesterase: nerve agents scavenger. Proteins. 2009 Nov 1;77(2):370-7.</reference_text>
      <pubmed_id>19452557</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F: Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem. 2003 Oct 17;278(42):41141-7. Epub 2003 Jul 17.</reference_text>
      <pubmed_id>12869558</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nachon F, Asojo OA, Borgstahl GE, Masson P, Lockridge O: Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. Biochemistry. 2005 Feb 1;44(4):1154-62.</reference_text>
      <pubmed_id>15667209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ngamelue MN, Homma K, Lockridge O, Asojo OA: Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Sep 1;63(Pt       9):723-7. Epub 2007 Aug 10.</reference_text>
      <pubmed_id>17768338</pubmed_id>
    </reference>
    <reference>
      <reference_text>Frasco MF, Colletier JP, Weik M, Carvalho F, Guilhermino L, Stojan J, Fournier D: Mechanisms of cholinesterase inhibition by inorganic mercury.  FEBS J. 2007 Apr;274(7):1849-61. Epub 2007 Mar 12.</reference_text>
      <pubmed_id>17355286</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carletti E, Li H, Li B, Ekstrom F, Nicolet Y, Loiodice M, Gillon E, Froment MT, Lockridge O, Schopfer LM, Masson P, Nachon F: Aging of cholinesterases phosphylated by tabun proceeds through O-dealkylation. J Am Chem Soc. 2008 Nov 26;130(47):16011-20.</reference_text>
      <pubmed_id>18975951</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carletti E, Aurbek N, Gillon E, Loiodice M, Nicolet Y, Fontecilla-Camps JC, Masson P, Thiermann H, Nachon F, Worek F: Structure-activity analysis of aging and reactivation of human butyrylcholinesterase inhibited by analogues of tabun. Biochem J. 2009 Jun 12;421(1):97-106.</reference_text>
      <pubmed_id>19368529</pubmed_id>
    </reference>
    <reference>
      <reference_text>McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN: Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7.</reference_text>
      <pubmed_id>2915989</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bartels CF, James K, La Du BN: DNA mutations associated with the human butyrylcholinesterase J-variant.  Am J Hum Genet. 1992 May;50(5):1104-14.</reference_text>
      <pubmed_id>1349196</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, Van der Spek AF, Lockridge O, La Du BN: Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. Am J Hum Genet. 1992 Oct;51(4):821-8.</reference_text>
      <pubmed_id>1415224</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hada T, Muratani K, Ohue T, Imanishi H, Moriwaki Y, Itoh M, Amuro Y, Higashino K: A variant serum cholinesterase and a confirmed point mutation at Gly-365 to Arg found in a patient with liver cirrhosis. Intern Med. 1992 Mar;31(3):357-62.</reference_text>
      <pubmed_id>1611188</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jensen FS, Bartels CF, La Du BN: Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families. Pharmacogenetics. 1992 Oct;2(5):234-40.</reference_text>
      <pubmed_id>1306123</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maekawa M, Sudo K, Kanno T, Kotani K, Dey DC, Ishikawa J, Izumi M, Etoh K: Genetic basis of the silent phenotype of serum butyrylcholinesterase in three compound heterozygotes. Clin Chim Acta. 1995 Feb 28;235(1):41-57.</reference_text>
      <pubmed_id>7634491</pubmed_id>
    </reference>
    <reference>
      <reference_text>Iida S, Kinoshita M, Fujii H, Moriyama Y, Nakamura Y, Yura N, Moriwaki K: Mutations of human butyrylcholinesterase gene in a family with hypocholinesterasemia. Hum Mutat. 1995;6(4):349-51.</reference_text>
      <pubmed_id>8680411</pubmed_id>
    </reference>
    <reference>
      <reference_text>Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AF, Innis JW, La Du BN: Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet. 1996 Jan;58(1):52-64.</reference_text>
      <pubmed_id>8554068</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hidaka K, Iuchi I, Tomita M, Watanabe Y, Minatogawa Y, Iwasaki K, Gotoh K, Shimizu C: Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency. Ann Hum Genet. 1997 Nov;61(Pt 6):491-6.</reference_text>
      <pubmed_id>9543549</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sudo K, Maekawa M, Akizuki S, Magara T, Ogasawara H, Tanaka T: Human butyrylcholinesterase L330I mutation belongs to a fluoride-resistant gene, by expression in human fetal kidney cells. Biochem Biophys Res Commun. 1997 Nov 17;240(2):372-5.</reference_text>
      <pubmed_id>9388484</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maekawa M, Sudo K, Dey DC, Ishikawa J, Izumi M, Kotani K, Kanno T: Genetic mutations of butyrylcholine esterase identified from phenotypic abnormalities in Japan. Clin Chem. 1997 Jun;43(6 Pt 1):924-9.</reference_text>
      <pubmed_id>9191541</pubmed_id>
    </reference>
    <reference>
      <reference_text>Primo-Parmo SL, Lightstone H, La Du BN: Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. Pharmacogenetics. 1997 Feb;7(1):27-34.</reference_text>
      <pubmed_id>9110359</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sakamoto N, Hidaka K, Fujisawa T, Maeda M, Iuchi I: Identification of a point mutation associated with a silent phenotype of human serum butyrylcholinesterase--a case of familial cholinesterasemia. Clin Chim Acta. 1998 Jun 22;274(2):159-66.</reference_text>
      <pubmed_id>9694584</pubmed_id>
    </reference>
    <reference>
      <reference_text>Asanuma K, Yagihashi A, Uehara N, Kida T, Watanabe N: Three point mutations of human butyrylcholinesterase in a Japanese family and the alterations of three-dimensional structure. Clin Chim Acta. 1999 May;283(1-2):33-42.</reference_text>
      <pubmed_id>10404729</pubmed_id>
    </reference>
    <reference>
      <reference_text>Boeck AT, Fry DL, Sastre A, Lockridge O: Naturally occurring mutation, Asp70his, in human butyrylcholinesterase.  Ann Clin Biochem. 2002 Mar;39(Pt 2):154-6.</reference_text>
      <pubmed_id>11928765</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yen T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM: Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clin Chem. 2003 Aug;49(8):1297-308.</reference_text>
      <pubmed_id>12881446</pubmed_id>
    </reference>
    <reference>
      <reference_text>On-Kei Chan A, Lam CW, Tong SF, Man Tung C, Yung K, Chan YW, Au KM, Yuen YP, Hung CT, Ng KP, Shek CC: Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity. Clin Chim Acta. 2005 Jan;351(1-2):155-9.</reference_text>
      <pubmed_id>15563885</pubmed_id>
    </reference>
    <reference>
      <reference_text>Manoharan I, Wieseler S, Layer PG, Lockridge O, Boopathy R: Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. Pharmacogenet Genomics. 2006 Jul;16(7):461-8.</reference_text>
      <pubmed_id>16788378</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gatke MR, Bundgaard JR, Viby-Mogensen J: Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. Pharmacogenet Genomics. 2007 Nov;17(11):995-9.</reference_text>
      <pubmed_id>18075469</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Ramipril</name>
        <accession>HMDB14324</accession>
      </metabolite>
      <reference>
        <reference_text>Shah GB, Sharma S, Mehta AA, Goyal RK: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000 Aug;36(2):169-75.</reference_text>
        <pubmed_id>10942157</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentagastrin</name>
        <accession>HMDB14329</accession>
      </metabolite>
      <reference>
        <reference_text>Chernysheva SV, Iaremko EE: [Cholinergic and hormonal correlations in the regulation of the secretory function of the small intestine]. Fiziol Zh SSSR Im I M Sechenova. 1983 Jun;69(6):827-31.</reference_text>
        <pubmed_id>6873393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Succinylcholine</name>
        <accession>HMDB14347</accession>
      </metabolite>
      <reference>
        <reference_text>Ostergaard D, Engbaek J, Viby-Mogensen J: Adverse reactions and interactions of the neuromuscular blocking drugs.  Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68.</reference_text>
        <pubmed_id>2682131</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Lim LY, Go ML: The anticholinesterase activity of mefloquine.  Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31.</reference_text>
        <pubmed_id>3878759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou C, Xiao C, McArdle JJ, Ye JH: Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther. 2006 Jun;317(3):1155-60. Epub 2006 Feb 24.</reference_text>
        <pubmed_id>16501066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>McArdle JJ, Sellin LC, Coakley KM, Potian JG, Quinones-Lopez MC, Rosenfeld CA, Sultatos LG, Hognason K: Mefloquine inhibits cholinesterases at the mouse neuromuscular junction.  Neuropharmacology. 2005 Dec;49(8):1132-9. Epub 2005 Aug 2.</reference_text>
        <pubmed_id>16081111</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Wang H, Tang XC: Anticholinesterase effects of huperzine A, E2020, and tacrine in rats.  Zhongguo Yao Li Xue Bao. 1998 Jan;19(1):27-30.</reference_text>
        <pubmed_id>10375753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Krustev AD, Argirova MD, Getova DP, Turiiski VI, Prissadova NA: Calcium-independent tacrine-induced relaxation of rat gastric corpus smooth muscles. Can J Physiol Pharmacol. 2006 Nov;84(11):1133-8.</reference_text>
        <pubmed_id>17218977</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Marco JL, Carreiras MC: Recent developments in the synthesis of acetylcholinesterase inhibitors.  Mini Rev Med Chem. 2003 Sep;3(6):518-24.</reference_text>
        <pubmed_id>12871155</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Ahmed M, Rocha JB, Correa M, Mazzanti CM, Zanin RF, Morsch AL, Morsch VM, Schetinger MR: Inhibition of two different cholinesterases by tacrine.  Chem Biol Interact. 2006 Aug 25;162(2):165-71. Epub 2006 Jun 17.</reference_text>
        <pubmed_id>16860785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulpiride</name>
        <accession>HMDB14535</accession>
      </metabolite>
      <reference>
        <reference_text>Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases.  Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201.</reference_text>
        <pubmed_id>3823608</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulpiride</name>
        <accession>HMDB14535</accession>
      </metabolite>
      <reference>
        <reference_text>Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6.</reference_text>
        <pubmed_id>577162</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethopropazine</name>
        <accession>HMDB14536</accession>
      </metabolite>
      <reference>
        <reference_text>Reiner E, Bosak A, Simeon-Rudolf V: Activity of cholinesterases in human whole blood measured with acetylthiocholine as substrate and ethopropazine as selective inhibitor of plasma butyrylcholinesterase. Arh Hig Rada Toksikol. 2004 Apr;55(1):1-4.</reference_text>
        <pubmed_id>15137175</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethopropazine</name>
        <accession>HMDB14536</accession>
      </metabolite>
      <reference>
        <reference_text>Sinko G, Kovarik Z, Reiner E, Simeon-Rudolf V, Stojan J: Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers. Biochimie. 2011 Oct;93(10):1797-807. Epub 2011 Jun 29.</reference_text>
        <pubmed_id>21740955</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipivefrin</name>
        <accession>HMDB14592</accession>
      </metabolite>
      <reference>
        <reference_text>Nakamura M, Shirasawa E, Hikida M: Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride. Ophthalmic Res. 1993;25(1):46-51.</reference_text>
        <pubmed_id>8446367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Nasello AG, Gidali D, Felicio LF: A comparative study of the anticholinesterase activity of several antipsychotic agents. Pharmacol Biochem Behav. 2003 Jul;75(4):895-901.</reference_text>
        <pubmed_id>12957233</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals.  Pharmacol Toxicol. 2003 Feb;92(2):100-4.</reference_text>
        <pubmed_id>12747580</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Spinedi A, Pacini L, Limatola C, Luly P, Farias RN: A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine.  Biochem J. 1991 Sep 1;278 ( Pt 2):461-3.</reference_text>
        <pubmed_id>1654884</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Bodur E: Human serum butyrylcholinesterase interactions with cisplatin and cyclophosphamide. Biochimie. 2010 Aug;92(8):979-84. Epub 2010 Apr 24.</reference_text>
        <pubmed_id>20417682</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dibucaine</name>
        <accession>HMDB14668</accession>
      </metabolite>
      <reference>
        <reference_text>Elamin B: Dibucaine inhibition of serum cholinesterase.  J Biochem Mol Biol. 2003 Mar 31;36(2):149-53.</reference_text>
        <pubmed_id>12689511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Somani SM, Husain K, Asha T, Helfert R: Interactive and delayed effects of pyridostigmine and physical stress on biochemical and histological changes in peripheral tissues of mice. J Appl Toxicol. 2000 Jul-Aug;20(4):327-34.</reference_text>
        <pubmed_id>10942908</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Servatius RJ, Ottenweller JE, Guo W, Beldowicz D, Zhu G, Natelson BH: Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats. Physiol Behav. 2000 May;69(3):239-46.</reference_text>
        <pubmed_id>10869589</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Abou-Donia MB, Wilmarth KR, Abdel-Rahman AA, Jensen KF, Oehme FW, Kurt TL: Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos. Fundam Appl Toxicol. 1996 Dec;34(2):201-22.</reference_text>
        <pubmed_id>8954750</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nizatidine</name>
        <accession>HMDB14723</accession>
      </metabolite>
      <reference>
        <reference_text>Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs.  Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93.</reference_text>
        <pubmed_id>8095733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6.</reference_text>
        <pubmed_id>17159811</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8.</reference_text>
        <pubmed_id>11888344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Wilkinson DG: Galantamine: a new treatment for Alzheimer's disease.  Expert Rev Neurother. 2001 Nov;1(2):153-9.</reference_text>
        <pubmed_id>19811027</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Kamata R, Saito S, Suzuki T, Takewaki T, Kobayashi H: Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen. Neurotoxicology. 2001 Apr;22(2):203-14.</reference_text>
        <pubmed_id>11405252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Acey RA, Bailey S, Healy P, Jo C, Unger TF, Hudson RA: A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity? Biochem Biophys Res Commun. 2002 Dec 13;299(4):659-62.</reference_text>
        <pubmed_id>12459190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Pittel Z, Cohen S, Fisher A, Heldman E: Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. Brain Res. 1992 Jul 17;586(1):148-51.</reference_text>
        <pubmed_id>1511344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Miller RB, Blank CL: Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection. Anal Biochem. 1991 Aug 1;196(2):377-84.</reference_text>
        <pubmed_id>1776688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol. 1990 Apr;99(4):721-6.</reference_text>
        <pubmed_id>2361169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Masson P, Fortier PL, Albaret C, Froment MT, Bartels CF, Lockridge O: Aging of di-isopropyl-phosphorylated human butyrylcholinesterase.  Biochem J. 1997 Oct 15;327 ( Pt 2):601-7.</reference_text>
        <pubmed_id>9359435</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Fujimaki Y, Sakamoto M, Shimada M, Kimura E, Aoki Y: Diethylcarbamazine: inhibitory effect on acetylcholinesterase of Dirofilaria immitis and Brugia pahangi. Southeast Asian J Trop Med Public Health. 1989 Jun;20(2):179-82.</reference_text>
        <pubmed_id>2609206</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Perez-Guillermo F, Delgado EM, Vidal CJ: Inhibition of human serum and rabbit muscle cholinesterase by local anesthetics.  Biochem Pharmacol. 1987 Nov 1;36(21):3593-6.</reference_text>
        <pubmed_id>3675616</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Dorokhov KE, Grigorian GL: [Binding of reversible spin-labeled inhibitors with an butyrylcholinesterase active center]. Biofizika. 1986 Sep-Oct;31(5):746-51.</reference_text>
        <pubmed_id>3022829</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Pohanka M, Jun D, Kuca K: In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048. J Enzyme Inhib Med Chem. 2009 Jun;24(3):680-3.</reference_text>
        <pubmed_id>18825528</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Khan S, Hemalatha R, Jeyaseelan L, Oommen A, Zachariah A: Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of butyrylcholinesterase. Hum Exp Toxicol. 2001 Apr;20(4):169-74.</reference_text>
        <pubmed_id>11393267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>Ramos ZR, Fortunato JJ, Agostinho FR, Martins MR, Correa M, Schetinger MR, Dal-Pizzol F, Quevedo J: Influence of malathion on acetylcholinesterase activity in rats submitted to a forced swimming test. Neurotox Res. 2006 Jun;9(4):285-90.</reference_text>
        <pubmed_id>16782587</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>Ahmed M, Rocha JB, Mazzanti CM, Morsch AL, Cargnelutti D, Correa M, Loro V, Morsch VM, Schetinger MR: Malathion, carbofuran and paraquat inhibit Bungarus sindanus (krait) venom acetylcholinesterase and human serum butyrylcholinesterase in vitro. Ecotoxicology. 2007 May;16(4):363-9. Epub 2007 Mar 16.</reference_text>
        <pubmed_id>17364237</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>da Silva AP, Meotti FC, Santos AR, Farina M: Lactational exposure to malathion inhibits brain acetylcholinesterase in mice.  Neurotoxicology. 2006 Dec;27(6):1101-5. Epub 2006 Apr 28.</reference_text>
        <pubmed_id>16716398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Malathion</name>
        <accession>HMDB14910</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perindopril</name>
        <accession>HMDB14928</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta A, Iyer L, Parmar S, Shah G, Goyal R: Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol. 2010 May;88(5):595-600.</reference_text>
        <pubmed_id>20555429</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Westlake GE, Bunyan PJ, Stanley PI, Walker CH: The effects of 1,1-di(p-chlorophenyl)-2-chloroethylene on plasma enzymes and blood constituents in the Japanese quail. Chem Biol Interact. 1979 May;25(2-3):197-210.</reference_text>
        <pubmed_id>466732</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbutaline</name>
        <accession>HMDB15009</accession>
      </metabolite>
      <reference>
        <reference_text>Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7.</reference_text>
        <pubmed_id>15449725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybuprocaine</name>
        <accession>HMDB15029</accession>
      </metabolite>
      <reference>
        <reference_text>Draeger J, Schloot W, Wirt H: Interindividual differences of corneal sensitivity. Genetic aspects.  Ophthalmic Paediatr Genet. 1985 Aug;6(1-2):291-5.</reference_text>
        <pubmed_id>4069587</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybuprocaine</name>
        <accession>HMDB15029</accession>
      </metabolite>
      <reference>
        <reference_text>Dubbels R, Schloot W: Studies on the metabolism of benoxinate by human pseudocholinesterase.  Metab Pediatr Syst Ophthalmol. 1983;7(1):37-43.</reference_text>
        <pubmed_id>6621359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hexafluronium</name>
        <accession>HMDB15076</accession>
      </metabolite>
      <reference>
        <reference_text>Schuh FR: Interaction of hexafluorenium with human plasma cholinesterase in comparison with hexamethonium. Naunyn Schmiedebergs Arch Pharmacol. 1976 Mar 24;293(1):11-3.</reference_text>
        <pubmed_id>948350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hexafluronium</name>
        <accession>HMDB15076</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Demecarium</name>
        <accession>HMDB15079</accession>
      </metabolite>
      <reference>
        <reference_text>Meiniel R: Neuromuscular blocking agents and axial teratogenesis in the avian embryo. Can axial morphogenetic disorders by explained by pharmacological action upon muscle tissue? Teratology. 1981 Apr;23(2):259-71.</reference_text>
        <pubmed_id>7196602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Demecarium</name>
        <accession>HMDB15079</accession>
      </metabolite>
      <reference>
        <reference_text>Gum GG, Gelatt KN, Gelatt JK, Jones R: Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93.</reference_text>
        <pubmed_id>8430939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclopentolate</name>
        <accession>HMDB15114</accession>
      </metabolite>
      <reference>
        <reference_text>Demayo AP, Reidenberg MM: Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled. Pediatrics. 2004 May;113(5):e499-500.</reference_text>
        <pubmed_id>15121994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.</reference_text>
        <pubmed_id>11078030</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682.</reference_text>
        <pubmed_id>11139819</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease.  Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191.</reference_text>
        <pubmed_id>19370562</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Birks J: Cholinesterase inhibitors for Alzheimer's disease.  Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.</reference_text>
        <pubmed_id>16437532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.</reference_text>
        <pubmed_id>19470293</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Smith DA: Treatment of Alzheimer's disease in the long-term-care setting.  Am J Health Syst Pharm. 2009 May 15;66(10):899-907.</reference_text>
        <pubmed_id>19420308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs. 2009;23(4):293-307.</reference_text>
        <pubmed_id>19374459</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia.  Expert Rev Neurother. 2008 Aug;8(8):1181-8.</reference_text>
        <pubmed_id>18671661</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update.  Clin Interv Aging. 2007;2(1):17-32.</reference_text>
        <pubmed_id>18044073</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Farlow MR: Update on rivastigmine.  Neurologist. 2003 Sep;9(5):230-4.</reference_text>
        <pubmed_id>14587496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.  Int Psychogeriatr. 2002;14 Suppl 1:77-91.</reference_text>
        <pubmed_id>12636181</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Harel M, Sussman JL, Krejci E, Bon S, Chanal P, Massoulie J, Silman I: Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10827-31.</reference_text>
        <pubmed_id>1438284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP: Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry. 1997 Dec 2;36(48):14642-51.</reference_text>
        <pubmed_id>9398183</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Bailey DN: Amitriptyline and procainamide inhibition of cocaine and cocaethylene degradation in human serum in vitro. J Anal Toxicol. 1999 Mar-Apr;23(2):99-102.</reference_text>
        <pubmed_id>10192412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procainamide</name>
        <accession>HMDB15169</accession>
      </metabolite>
      <reference>
        <reference_text>Page JD, Wilson IB, Silman I: Butyrylcholinesterase: inhibition by arsenite, fluoride, and other ligands, cooperativity in binding. Mol Pharmacol. 1985 Apr;27(4):437-43.</reference_text>
        <pubmed_id>3982389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Echothiophate</name>
        <accession>HMDB15190</accession>
      </metabolite>
      <reference>
        <reference_text>Henderson EG, Post-Munson DJ, Reynolds LS, Epstein PM: Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle. J Pharmacol Exp Ther. 1989 Dec;251(3):810-6.</reference_text>
        <pubmed_id>2481033</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Echothiophate</name>
        <accession>HMDB15190</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethaphan</name>
        <accession>HMDB15248</accession>
      </metabolite>
      <reference>
        <reference_text>Nakamura K, Koide M, Imanaga T, Ogasawara H, Takahashi M, Yoshikawa M: Prolonged neuromuscular blockade following trimetaphan infusion. A case report and in vitro study of cholinesterase inhibition. Anaesthesia. 1980 Dec;35(12):1202-7.</reference_text>
        <pubmed_id>7457791</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Yamamoto K, Kohda Y, Sawada Y, Iga T: Pharmacokinetics of ambenonium, a reversible cholinesterase inhibitor, in rats.  Biopharm Drug Dispos. 1991 Nov;12(8):613-25.</reference_text>
        <pubmed_id>1801966</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxacurium chloride</name>
        <accession>HMDB15266</accession>
      </metabolite>
      <reference>
        <reference_text>Basta SJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastila WB: Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant. Anesthesiology. 1988 Oct;69(4):478-86.</reference_text>
        <pubmed_id>2972233</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxacurium chloride</name>
        <accession>HMDB15266</accession>
      </metabolite>
      <reference>
        <reference_text>Dresner DL, Basta SJ, Ali HH, Schwartz AF, Embree PB, Wargin WA, Lai AA, Brady KA, Savarese JJ: Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth Analg. 1990 Nov;71(5):498-502.</reference_text>
        <pubmed_id>2145783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Kuhnert BR, Philipson EH, Pimental R, Kuhnert PM: A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase. Anesthesiology. 1982 Jun;56(6):477-8.</reference_text>
        <pubmed_id>7081736</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Tucker GT, Mather LE: Clinical pharmacokinetics of local anaesthetics.  Clin Pharmacokinet. 1979 Jul-Aug;4(4):241-78.</reference_text>
        <pubmed_id>385208</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Monedero P, Hess P: High epidural block with chloroprocaine in a parturient with low pseudocholinesterase activity. Can J Anaesth. 2001 Mar;48(3):318-9.</reference_text>
        <pubmed_id>11305839</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Smith AR, Hur D, Resano F: Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency. Anesth Analg. 1987 Jul;66(7):677-8.</reference_text>
        <pubmed_id>3111302</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Raj PP, Ohlweiler D, Hitt BA, Denson DD: Kinetics of local anesthetic esters and the effects of adjuvant drugs on 2-chloroprocaine hydrolysis. Anesthesiology. 1980 Oct;53(4):307-14.</reference_text>
        <pubmed_id>7425357</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mivacurium</name>
        <accession>HMDB15357</accession>
      </metabolite>
      <reference>
        <reference_text>Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade.  Can J Anaesth. 1996 Nov;43(11):1128-33.</reference_text>
        <pubmed_id>8922768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Munoz-Delgado E, Vidal CJ: Kinetic behaviour of acetylcholinesterase from muscle microsomal membranes.  Biochem Int. 1986 Oct;13(4):625-32.</reference_text>
        <pubmed_id>3801037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Danilov AF: [Inhibition of cholinesterase in the myoneural synapses by decamethonium and ditilin]. Farmakol Toksikol. 1967 Nov-Dec;30(6):664-9.</reference_text>
        <pubmed_id>5598433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pancuronium</name>
        <accession>HMDB15430</accession>
      </metabolite>
      <reference>
        <reference_text>Stovner J, Oftedal N, Holmboe J: The inhibition of cholinesterases by pancuronium.  Br J Anaesth. 1975 Sep;47(9):949-54.</reference_text>
        <pubmed_id>1191483</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pipecuronium</name>
        <accession>HMDB15431</accession>
      </metabolite>
      <reference>
        <reference_text>Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3.</reference_text>
        <pubmed_id>6248079</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Maizel' EB, Rozengart EV, Khakimov IuP, Abduvakhabov AA, Aslanov KhA: [Ephedrine, salsoline and cytisine derivatives as substrates and inhibitirs of cholinesterases]. Biokhimiia. 1978 Jul;43(7):1150-6.</reference_text>
        <pubmed_id>698301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Koitka M, Hochel J, Gieschen H, Borchert HH: Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J Pharm Biomed Anal. 2010 Feb 5;51(3):664-78. Epub 2009 Sep 23.</reference_text>
        <pubmed_id>19850433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Saito S: Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons. Neurotoxicol Teratol. 1998 Jul-Aug;20(4):411-9.</reference_text>
        <pubmed_id>9697967</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bambuterol</name>
        <accession>HMDB15478</accession>
      </metabolite>
      <reference>
        <reference_text>Gazic I, Bosak A, Sinko G, Vinkovic V, Kovarik Z: Preparative HPLC separation of bambuterol enantiomers and stereoselective inhibition of human cholinesterases. Anal Bioanal Chem. 2006 Aug;385(8):1513-9. Epub 2006 Jul 25.</reference_text>
        <pubmed_id>16865342</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Substance P</name>
        <accession>HMDB01897</accession>
      </metabolite>
      <reference>
        <reference_text>Lockridge O: Substance P hydrolysis by human serum cholinesterase.  J Neurochem. 1982 Jul;39(1):106-10.</reference_text>
        <pubmed_id>6177830</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>R-95913</name>
        <accession>HMDB13930</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
